论文部分内容阅读
目的:探讨Irisin在非酒精性脂肪肝(NAFLD)患者肝穿刺组织中的表达及其意义。方法:回顾性分析病理活检确诊的非酒精性单纯性脂肪肝(NAFL,n=56)、非酒精性脂肪性肝炎(NASH,n=75)患者及无脂肪变和脂肪性肝炎的正常者(n=20)的临床资料,免疫组化SP法检测各组肝穿刺组织中Irisin的表达水平。结果:3组年龄及性别构成比差异无统计学意义(P>0.05)。与正常对照组相比,NAFL组及NASH组存在脂质代谢异常。NAFL组和NASH组肝组织中Irisin表达水平高于对照组(P<0.05),但NAFL组和NASH组间差异无统计学意义(P>0.05)。结论:Irisin可能是一种补偿性调节肝脏脂质蓄积的因子。
Objective: To investigate the expression and significance of Irisin in hepatic puncture tissue of patients with non-alcoholic fatty liver disease (NAFLD). Methods: Retrospective analysis of pathologically confirmed non-alcoholic fatty liver (NAFL, n = 56), patients with non-alcoholic steatohepatitis (NASH, n = 75) and those without steatosis and steatohepatitis n = 20). The immunohistochemical SP method was used to detect the expression of Irisin in liver biopsy tissues. Results: There were no significant differences in the age and gender composition ratio between the three groups (P> 0.05). Compared with normal control group, NAFL group and NASH group had abnormal lipid metabolism. The level of Irisin in NAFL group and NASH group was higher than that in control group (P <0.05), but there was no significant difference between NAFL group and NASH group (P> 0.05). Conclusion: Irisin may be a compensatory regulator of hepatic lipid accumulation.